The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy
Open accessAbstract
SUMMARY The human TEAD family of transcription factors (TEAD1-4) is required for YAP-mediated transcription in the Hippo pathway. Hyperactivation of TEAD’s co-activator YAP contributes to tissue overgrowth and human cancers, suggesting that pharmacological interference of TEAD-YAP activity may be an effective strategy for anticancer therapy. Here we report the discovery of a central pocket in the YAP-binding domain (YBD) of TEAD that is targetable by small molecule inhibitors. Our X-ray crystallography studies reveal that flufenamic acid, a non-steroidal anti-inflammatory drug (NSAID), binds to the central pocket of TEAD2 YBD. Our biochemical and functional analyses further demonstrate that binding of NSAIDs to TEAD inhibits TEAD-YAP-dependent transcription, cell migration and proliferation, indicating that the central pocket is important for TEAD function. Therefore, our studies discover a novel way of targeting TEAD transcription factors and set the stage for therapeutic development of specific TEAD-YAP inhibitors against human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“Phases were obtained by molecular replacementwith Phaser (McCoy et al., 2007) using the crystal structure of humanTEAD2YBDdomain (PDB: 3L15) as the searchmodel.”
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“However, the distance between interfaces 2 and 3 imposes a lower size limit on a dual-site ligand that is larger than what is generally deemed acceptable for small drug-like molecules (Veber et al., 2002).”
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 2×
“Remarkably, YAP and TAZ, with the help of TEADs, endow cells with many such attributes, such as resistance to contact inhibition (Zhao et al., 2007), ability to sustain anchorage independent growth (Overholtzer et al., 2006), transition to a mesenchymal state for migration, invasion and maintenance…”
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 1×
“Hyperactivation of TEAD-YAP contributes to various human cancers, such as prostate cancer (Knight et al., 2008) and pancreatic cancer (Hucl et al., 2007; Kapoor et al., 2014).”
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.009 · Cited by 326
The Hippo signal transduction network in skeletal and cardiac muscle
Wackerhage, H., Del Re, D. P., Judson, R. N., Sudol, M., & Sadoshima, J. (2014) · Science Signaling · doi:10.1126/scisignal.2005096 · Cited by 92
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities
Calses, P. C., Crawford, J. J., Lill, J. R., & Dey, A. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.001 · Cited by 420
Regulation of the Hippo Pathway Transcription Factor TEAD
Lin, K. C., Park, H. W., & Guan, K.-L. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.09.003 · Cited by 332
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313
“In addition, another hydrophobic pocket near the surface is close to C348 in TEAD2 structure, which could accommodate the binding of hydrophobic ligands, such as bromofenamic acid (BFA) 45 .”
Self-citationNoland, C. L., Gierke, S., Schnier, P. D., Murray, J., Sandoval, W. N., Sagolla, M., Dey, A., Hannoush, R. N., Fairbrother, W. J., & Cunningham, C. N. (2016) · Structure · doi:10.1016/j.str.2015.11.005 · Cited by 262
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy
Thompson, B. J. (2020) · BioEssays · doi:10.1002/bies.201900162 · Cited by 259
Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
Self-citationCovalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
Fan, M., Lu, W., Che, J., Kwiatkowski, N. P., Gao, Y., Seo, H.-S., Ficarro, S. B., Gokhale, P. C., Liu, Y., Geffken, E. A., et al. (2022) · eLife · doi:10.7554/elife.78810 · Cited by 68
Metadata
- Authors
- Pobbati, A. V., Han, X., Hung, A. W., Weiguang, S., Huda, N., Chen, G.-Y., Kang, C., Chia, C. S. B., Luo, X., Hong, W., & Poulsen, A.
- Venue
- Structure
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 23
- Issue
- 11
- Pages
- 2076-2086
- ISSN
- 0969-2126 (ISSN-L)
- OpenAlex
- W1761618837
- Cited by
- 206
- References
- 10
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.